Life Science Nation Newsletter | January 31, 2019 | Issue 302

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
RESI Europe Super Early Bird Ends Tomorrow
Use Code SUPEREBEU to Save €100
   Life Science Investor Mandates
(Jan. 24 - Jan. 30 )
Seeks to Partner and Invest in Oncology & Metabolic Disease Therapeutics
Invests in Early-Stage Medical Device and Diagnostics Companies in USA and Canada
Invests in Novel Therapeutics Across Oncology, CNS, Infectious Disease, and More Throughout USA, Europe, and China
Establishes Dedicated Health Tech Fund to Invest Up to $10M in Promising Medical Devices, Diagnostics, and Digital Health Companies
LSN Services
LSN Videos
LSN Media Partners
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Life Science Nation (LSN) is bringing the Redefining Early Stage Investments (RESI) Conference series to Vienna on March 25th. In an effort to spread the word about RESI coming to Europe, myself, Greg Mannix (VP International BD, LSN) and Patrik Frei, (CEO, Venture Valuation (VV)) are heading out to give one-day boot camps on global fundraising, company valuation and licensing deal metrics.

The road trip will be quite the adventure. Starting tomorrow, I arrive in London for a round of discussion with some tech hub players, then off to Paris to do a workshop at Medicene, then on to Gothenburg and the AstraZeneca BioventureHub, then up to Stockholm with Sweden Bio at the H2 Health Hub, then on to the Novo Nordisk BioInnovation Institute in Copenhagen and finishing in Spain at the University of Barcelona Science Park. The LSN Fundraising Boot Camp is a vehicle to help startups and potential RESI attendees sharpen up their partner pitches, improve their marketing packages and help them address the all-important topics of valuation and licensing strategy, in addition to informing entrepreneurs about the ten categories of global investors that will be attending RESI. RESI is expected to bring 200-300 early-stage investors to gather in Vienna, including VC, PE, Big Pharma, Foundations, Angels, as well as featuring the Global Family Office BioForum led by Stetson Family Office...

RESI Europe Innovation Challenge Application Deadline: February 20th, 2019
By Lucy Parkinson, VP of Investor Research, LSN

In addition to RESI's industry leading one-on-one partnering experience, RESI Europe also features an agenda of panels focused on informing entrepreneurs on how to go about raising capital for their life science technologies.   While panels span various investor groups (such as Family Offices and Big Pharma) and industry verticals (such as Diagnostic Investors and Medical Device Investors), all are aimed at providing RESI's entreprenerial attendees with insight from the other side of the table.   Today, LSN would like to introduce you to some of our RESI Europe panelists - all of whom are experienced investors or strategic business development staff who are actively making deals with startups in the life science space.

  • Tony Chang - M Ventures (Digital Health Investors)
  • Diana Saraceni - Panakes Partners (Medical Device Investors)
  • Christopher de Souza - Broadview Ventures (Family Offices & Angels)
  • Natalia Novac - Eli Lilly & Co (Big Pharma)
  • Tom Miller - GreyBird Ventures (Diagnostic Investors)

Zohar Beeri
An interview with Zohar Beeri, Chairman & CEO, Novotalk
- By Karen Deyo, Investor Research Analyst, LSN
Karen Deyo

Imagine you speak with a stutter. You take a speech therapy class, and it works! The stutter is gone. However, the symptoms start to come back, and you realize that only continuous practice will maintain your progress. So you create an app for that. This was the beginning of Novotalk, which aims to be a full-service speech therapy digital platform, helpful for all types of speech therapy, accessible to patients 24/7 and eliminating the need for office visits. This technology would allow patients to practice when they need it, would give measurable outcomes and could alter treatment strategies if necessary, to improve efficacy. I spoke with Zohar, who, along with his colleagues Lilach and Jonathan, generated a lot of excitement around Novotalk's technology, winning 1 st place in the Innovation Challenge at RESI SF on Jan 8 th.

Karen Deyo (KD): Congratulations Zohar on winning the IC. How was your first experience at RESI?

Zohar Beeri (ZB):  Before coming to RESI, one of my colleagues was a bit skeptical, but at the end of the day, we all thought it was great! Having a conference dedicated to early-stage investing, with the speed-dating style meetings was very useful for making a lot of good connections with investors. There is no other event like it...

Created & Produced by